Compass Therapeutics, Inc. (CMPX)
| Market Cap | 178.83M -71.1% |
| Revenue (ttm) | n/a |
| Net Income | -73.45M |
| EPS | -0.40 |
| Shares Out | 180.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,670,593 |
| Open | 0.9932 |
| Previous Close | 0.9834 |
| Day's Range | 0.9779 - 1.0500 |
| 52-Week Range | 0.8294 - 6.8800 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 5.45 (+448.84%) |
| Est. Earnings | Nov 4, 2026 |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CMPX stock is "Buy." The 12-month stock price target is $5.45, which is an increase of 448.84% from the latest price.
News
Compass Therapeutics price target lowered to $8 from $15 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Compass Therapeutics (CMPX) to $8 from $15 and keeps a Buy rating on the shares following FDA’s feedback that precludes tovecimig’s path forward…
Wedbush downgrades Compass Therapeutics as FDA throws wrench at tovecimig
As previously reported, Wedbush downgraded Compass Therapeutics (CMPX) to Neutral from Outperform with a price target of $1, down from $5. The firm notes the company announced that the FDA…
Compass Therapeutics price target lowered to $4 from $8 at Guggenheim
Guggenheim lowered the firm’s price target on Compass Therapeutics (CMPX) to $4 from $8 and keeps a Buy rating on the shares after the FDA recommended that Compass conduct a…
Compass Therapeutics price target lowered to $12 from $24 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Compass Therapeutics (CMPX) to $12 from $24 and keeps a Buy rating on the shares. The FDA wants a trial demonstrating a…
Compass Therapeutics price target lowered to $4 from $10 at Citizens
Citizens lowered the firm’s price target on Compass Therapeutics (CMPX) to $4 from $10 and keeps an Outperform rating on the shares. Compass is continuing discussions with the FDA after…
Compass Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Compass Therapeutics (CMPX) to Neutral from Outperform with a price target of $1, down from $5.
Compass Therapeutics downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform.
Compass Therapeutics says FDA requests new trial for tovecimig
Compass Therapeutics (CMPX) announced that the Food and Drug Administration recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a biologics license applica...
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass Therapeutics price target raised to $7 from $4 at Leerink
Leerink raised the firm’s price target on Compass Therapeutics (CMPX) to $7 from $4 and keeps an Outperform rating on the shares.
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior t...
Compass Therapeutics Earnings release: Q2 2026
Compass Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Compass Therapeutics Quarterly report: Q2 2026
Compass Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Four oncology assets are advancing, with lead drug tovecimig showing strong efficacy in BTC and moving toward FDA submission. Multiple clinical and regulatory catalysts are expected in the next year, supported by a cash runway into 2028.
Compass Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Lead oncology asset tovecimig demonstrated significant efficacy in biliary tract cancer, with plans for FDA submission and further studies underway. Promising early results from PD-1/PD-L1 bispecific and CD137 agonist programs, with multiple data updates expected later this year.
Compass Therapeutics to Participate in Upcoming June Investor Events
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Significant PFS and ORR results for tovecimig support a planned BLA submission, with FDA feedback expected by Labor Day and confirmatory study designs under consideration. CTX-8371 data will debut at ASCO, and strong cash reserves support ongoing clinical and pipeline expansion.
Compass Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The company highlighted strong phase II/III data for its lead bispecific antibody in biliary tract cancer, with plans for FDA submission and significant commercial potential. Pipeline updates include promising early results for PD-1/PD-L1 and PD-1/VEGF bispecifics, and a new phase II study for a CD137 agonist.
Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
“We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year. Most patients with…
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics Earnings release: Q1 2026
Compass Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Compass Therapeutics Quarterly report: Q1 2026
Compass Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.